Precision Therapy for Mesothelioma: Feasibility and New Opportunities

Malignant pleural mesotheliomas (MPMs) are characterised by their wide variation in natural history, ranging from minimally to highly aggressive, associated with both interpatient and intra-tumour genomic heterogeneity. Recent insights into the nature of this genetic variation, the identification of drivers, and the emergence of novel strategies capable of targeting vulnerabilities that result from the inactivation of key tumour suppressors suggest that new approaches to molecularly strategy therapy for mesothelioma may be feasible.

Automated summary

Malignant pleural mesotheliomas (MPMs) exhibit a wide variation in natural history and genomic heterogeneity among patients and within tumors. Recent advancements in identifying genetic drivers and developing strategies to target vulnerabilities resulting from inactivation of key tumor suppressors suggest potential for novel molecular therapy approaches for mesothelioma.